The global hemophilia market reached a value of US$ 10.5 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 20.1 Billion by 2027, exhibiting a CAGR of 11.5% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

Hemophilia is a rare disorder wherein the blood clotting process is slowed due to the lack of sufficient blood-clotting proteins. Patients with this condition experience prolonged bleeding or oozing after an injury, surgery, or a tooth is pulled. In severe cases, continuous bleeding may also occur after minor trauma or even in the absence of injury. On the other hand, its milder form does not involve spontaneous bleeding. As a result, the condition may not become apparent until abnormal bleeding occurs.

Hemophilia Market Trends:
The rising number of hemophilic patients around the world represents one of the key factors propelling the growth of the market. Additionally, the increasing diagnosis rate and the growing use of prophylactic treatment for hemophilia are offering lucrative growth opportunities to leading market players. Apart from this, due to the availability of limited treatment therapy, governing agencies of numerous countries are funding research and development (R&D) activities to identify therapeutic agents. They are also launching numerous campaigns to generate awareness about early diagnosis and undertaking initiatives to commence early screening of neonates. This is positively influencing the need for diagnostic tools of hemophilia worldwide. Besides this, the rising number of organizations like the World Federation of Hemophilia (WFH) and the National Hemophilia Foundation (NHF) is also impelling the market growth. These organizations help find treatments for inheritable bleeding disorders and prevent complications of these disorders through education, research, and advocacy. Furthermore, several companies are adopting strategies for increasing their sales and geographic expansion, especially in the Middle Eastern and West African countries. For instance, BioMarin Pharmaceutical Inc. is focusing on the development of Valoctocogene Roxaparvovec (BMN-270) for treating type A patients.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global hemophilia market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on type, treatment and therapy.

Breakup by Type:

Hemophilia A
Hemophilia B
Hemophilia C
Others

Breakup by Treatment:

On-Demand
Prophylaxis

Breakup by Therapy:

Replacement Therapy
ITI Therapy
Gene Therapy

Breakup by Region:

North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Baxter International Inc., Bayer AG, BioMarin Pharmaceutical Inc., CSL Behring (CSL Limited), F. Hoffmann-La Roche AG, Grifols S.A., Kedrion S.p.A., Novo Nordisk A/S, Octapharma AG, Pfizer Inc., Sanofi S.A. and Takeda Pharmaceutical Company Limited.

Key questions answered in this report:
How has the global hemophilia market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global hemophilia market?
What are the key regional markets?
What is the breakup of the market based on the type?
What is the breakup of the market based on the treatment?
What is the breakup of the market based on the therapy?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global hemophilia market and who are the key players?
What is the degree of competition in the industry?